gabapentin has been researched along with Abnormalities, Drug-Induced in 12 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
Excerpt | Relevance | Reference |
---|---|---|
"Our objectives were to 1) determine whether first-trimester use of gabapentin is associated with an increased risk for major malformations; 2) examine rates of spontaneous abortions, therapeutic abortions, stillbirths, mean birth weight and gestational age at delivery; and 3) examine rates of poor neonatal adaptation syndrome following late pregnancy exposure." | 9.17 | Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. ( Bernard, N; Einarson, A; Einarson, TR; Etwell, F; Fujii, H; Goel, A; Han, JY; Koren, G; Matsui, D; Pistelli, A; Stephens, S; Yates, LM, 2013) |
" We examined the risk of major congenital malformations and cardiac defects associated with gabapentin exposure during the first trimester (T1), and the risk of preeclampsia (PE), preterm birth (PTB), small for gestational age (SGA), and neonatal intensive care unit admission (NICUa) associated with gabapentin exposure early, late, or both early and late in pregnancy." | 7.96 | Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. ( Bateman, BT; Cohen, JM; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Patorno, E, 2020) |
"Our objectives were to 1) determine whether first-trimester use of gabapentin is associated with an increased risk for major malformations; 2) examine rates of spontaneous abortions, therapeutic abortions, stillbirths, mean birth weight and gestational age at delivery; and 3) examine rates of poor neonatal adaptation syndrome following late pregnancy exposure." | 5.17 | Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. ( Bernard, N; Einarson, A; Einarson, TR; Etwell, F; Fujii, H; Goel, A; Han, JY; Koren, G; Matsui, D; Pistelli, A; Stephens, S; Yates, LM, 2013) |
" We examined the risk of major congenital malformations and cardiac defects associated with gabapentin exposure during the first trimester (T1), and the risk of preeclampsia (PE), preterm birth (PTB), small for gestational age (SGA), and neonatal intensive care unit admission (NICUa) associated with gabapentin exposure early, late, or both early and late in pregnancy." | 3.96 | Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. ( Bateman, BT; Cohen, JM; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Patorno, E, 2020) |
"A total of 60 pregnant mice, divided into 12 groups of five mice each, were exposed to gabapentin in four different doses of 0 (control), 113, 226, or 452 mg/kg body weight per day, at three different gestational stages including early gestation (1-6 days), mid-gestation (7-12 days), and late gestation (13-17 days)." | 3.74 | Teratogenic effects of the anticonvulsant gabapentin in mice. ( Goel, RK; Madhyastha, S; Nasar, MA; Pai, MM; Prabhu, LV; Rai, R; Singh, G; Yadav, SK, 2008) |
" In the last decade, pregnancy registries have been activated by collaborative groups of physicians in Europe (EURAP), North America (NAREP), Australia and India (the latter two recently merged into EURAP), to enroll a large number of exposed women to be monitored prospectively with standardized methods, and by three pharmaceutical companies marketing lamotrigine, gabapentin and vigabatrin, as part of their post-marketing surveillance." | 3.71 | Pregnancy registries in epilepsy. ( Annegers, JF; Beghi, E, 2001) |
" It still remains unclear how much these drugs are safe during pregnancy." | 1.51 | The neurotoxic effects of prenatal gabapentin and oxcarbazepine exposure on newborn rats. ( Ayas, B; Ercument Beyhun, N; Erisgin, Z; Nyengaard, JR; Terzi, Y, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (16.67) | 18.2507 |
2000's | 4 (33.33) | 29.6817 |
2010's | 5 (41.67) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
Authors | Studies |
---|---|
Patorno, E | 1 |
Hernandez-Diaz, S | 2 |
Huybrechts, KF | 1 |
Desai, RJ | 1 |
Cohen, JM | 1 |
Mogun, H | 1 |
Bateman, BT | 1 |
Erisgin, Z | 1 |
Ayas, B | 1 |
Nyengaard, JR | 1 |
Ercument Beyhun, N | 1 |
Terzi, Y | 1 |
Fujii, H | 1 |
Goel, A | 1 |
Bernard, N | 1 |
Pistelli, A | 1 |
Yates, LM | 1 |
Stephens, S | 1 |
Han, JY | 1 |
Matsui, D | 1 |
Etwell, F | 1 |
Einarson, TR | 1 |
Koren, G | 1 |
Einarson, A | 1 |
Yüksel, M | 1 |
Sarıkaya, R | 1 |
Bostanci, N | 1 |
Holmes, LB | 1 |
Koo, J | 1 |
Zavras, A | 1 |
Prabhu, LV | 1 |
Rai, R | 1 |
Pai, MM | 1 |
Yadav, SK | 1 |
Madhyastha, S | 1 |
Goel, RK | 1 |
Singh, G | 1 |
Nasar, MA | 1 |
Appleton, RE | 1 |
Tueth, MJ | 1 |
Murphy, TK | 1 |
Evans, DL | 1 |
Iqbal, MM | 1 |
Gundlapalli, SP | 1 |
Ryan, WG | 1 |
Ryals, T | 1 |
Passman, TE | 1 |
Beghi, E | 1 |
Annegers, JF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum[NCT02163434] | Phase 2 | 31 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Score range: 6-30 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week
Intervention | units on a scale (Mean) |
---|---|
Gabapentin | 6.35 |
Metoclopramide | 13.22 |
Score range: 2-10 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week
Intervention | units on a scale (Mean) |
---|---|
Gabapentin | 2.01 |
Metoclopramide | 3.69 |
Score range: 0-15 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week
Intervention | units on a scale (Mean) |
---|---|
Gabapentin | 7.86 |
Metoclopramide | 4.01 |
Scores: 0=no, 1=yes. Thus, a higher score indicates a better outcome. (NCT02163434)
Timeframe: 1 week
Intervention | units on a scale (Mean) |
---|---|
Gabapentin | 0.67 |
Metoclopramide | 0.14 |
Score range: 0-4 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week
Intervention | units on a scale (Mean) |
---|---|
Gabapentin | 2.22 |
Metoclopramide | 0.63 |
(NCT02163434)
Timeframe: 1 week
Intervention | Participants (Count of Participants) |
---|---|
Gabapentin | 5 |
Metoclopramide | 5 |
3 reviews available for gabapentin and Abnormalities, Drug-Induced
Article | Year |
---|---|
The new antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Amines; Anticonvulsants; Child; Child, Pre | 1996 |
Special considerations: use of lithium in children, adolescents, and elderly populations.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Age Factors; Aged; Amines; Anticonvulsants | 1998 |
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Antimanic Agents; Benzodiazepines; Breast Feed | 2001 |
1 trial available for gabapentin and Abnormalities, Drug-Induced
Article | Year |
---|---|
Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study.
Topics: Abnormalities, Drug-Induced; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Ga | 2013 |
8 other studies available for gabapentin and Abnormalities, Drug-Induced
Article | Year |
---|---|
Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset.
Topics: Abnormalities, Drug-Induced; Adult; Cohort Studies; Female; Gabapentin; Humans; Infant, Small for Ge | 2020 |
The neurotoxic effects of prenatal gabapentin and oxcarbazepine exposure on newborn rats.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Brain; Dopaminergic Neurons; Female; Gabapen | 2019 |
Genotoxic evaluation of antiepileptic drugs by Drosophila somatic mutation and recombination test.
Topics: Abnormalities, Drug-Induced; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Drosophi | 2010 |
Newer anticonvulsants: lamotrigine, topiramate and gabapentin.
Topics: Abnormalities, Drug-Induced; Adult; Amines; Anticonvulsants; Case-Control Studies; Child; Child, Pre | 2012 |
Antiepileptic drugs (AEDs) during pregnancy and risk of congenital jaw and oral malformation.
Topics: Abnormalities, Drug-Induced; Adverse Drug Reaction Reporting Systems; Amines; Anticonvulsants; Cyclo | 2013 |
Teratogenic effects of the anticonvulsant gabapentin in mice.
Topics: Abnormalities, Drug-Induced; Amines; Animals; Anticonvulsants; Body Weight; Congenital Abnormalities | 2008 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
Pregnancy registries in epilepsy.
Topics: Abnormalities, Drug-Induced; Acetates; Amines; Anticonvulsants; Australia; Cross-Cultural Comparison | 2001 |